Drug intelligence / Profile preview

fenghuaqinaqingfang

Development stage: Preclinical
Lead developer: Guangzhou Hongyun Medical Scientific and Technological
Administration: Oral

Overview

Fenghuaqinaqingfang is a drug currently under investigation for the prevention and treatment of benign prostatic hyperplasia and chronic prostatitis. Clinical trials describe its administration as a preparation, possibly in bags or pieces, taken orally. The specific mechanism of action is not detailed in the available information. Guangzhou Hongyun Medical Scientific and Technological Co., Ltd is involved in running the clinical trials for this drug.

Other names: fenghuaqinaqingcha

Beyond the preview

Go deeper on fenghuaqinaqingfang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fenghuaqinaqingfang.

Explore the full profile